These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 16495254

  • 1. Population pharmacokinetics of liposomal amphotericin B in pediatric patients with malignant diseases.
    Hong Y, Shaw PJ, Nath CE, Yadav SP, Stephen KR, Earl JW, McLachlan AJ.
    Antimicrob Agents Chemother; 2006 Mar; 50(3):935-42. PubMed ID: 16495254
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetic evaluation of liposomal amphotericin B (L-AMB) in patients with invasive fungal infection: Population approach in Japanese pediatrics.
    Ohata Y, Tomita Y, Suzuki K, Maniwa T, Yano Y, Sunakawa K.
    Drug Metab Pharmacokinet; 2015 Dec; 30(6):400-9. PubMed ID: 26645511
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics of amphotericin B in children with malignant diseases.
    Nath CE, McLachlan AJ, Shaw PJ, Gunning R, Earl JW.
    Br J Clin Pharmacol; 2001 Dec; 52(6):671-80. PubMed ID: 11736878
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G.
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics of ciprofloxacin in pediatric patients.
    Rajagopalan P, Gastonguay MR.
    J Clin Pharmacol; 2003 Jul; 43(7):698-710. PubMed ID: 12856383
    [Abstract] [Full Text] [Related]

  • 6. Amphotericin B dose optimization in children with malignant diseases.
    Nath CE, McLachlan AJ, Shaw PJ, Coakley JC, Earl JW.
    Chemotherapy; 2007 Jul; 53(2):142-7. PubMed ID: 17310120
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens.
    Hope WW, Goodwin J, Felton TW, Ellis M, Stevens DA.
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5303-8. PubMed ID: 22869566
    [Abstract] [Full Text] [Related]

  • 8. Plasma protein distribution and its impact on pharmacokinetics of liposomal amphotericin B in paediatric patients with malignant diseases.
    Hong Y, Shaw PJ, Tattam BN, Nath CE, Earl JW, Stephen KR, McLachlan AJ.
    Eur J Clin Pharmacol; 2007 Feb; 63(2):165-72. PubMed ID: 17180621
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients.
    Würthwein G, Young C, Lanvers-Kaminsky C, Hempel G, Trame MN, Schwerdtfeger R, Ostermann H, Heinz WJ, Cornely OA, Kolve H, Boos J, Silling G, Groll AH.
    Antimicrob Agents Chemother; 2012 Jan; 56(1):536-43. PubMed ID: 22083471
    [Abstract] [Full Text] [Related]

  • 13. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [Abstract] [Full Text] [Related]

  • 14. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
    Mehta P, Vinks A, Filipovich A, Vaughn G, Fearing D, Sper C, Davies S.
    Biol Blood Marrow Transplant; 2006 Feb; 12(2):235-40. PubMed ID: 16443521
    [Abstract] [Full Text] [Related]

  • 15. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE, Tett SE.
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [Abstract] [Full Text] [Related]

  • 16. Population pharmacokinetics of amphotericin B lipid complex in neonates.
    Würthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ.
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5092-8. PubMed ID: 16304177
    [Abstract] [Full Text] [Related]

  • 17. Clinical and pharmacokinetic evaluation of a new lipid-based delivery system of amphotericin B in AIDS patients.
    Villani P, Regazzi MB, Maserati R, Viale P, Alberici F, Giacchino R.
    Arzneimittelforschung; 1996 Apr; 46(4):445-9. PubMed ID: 8740098
    [Abstract] [Full Text] [Related]

  • 18. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
    Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ.
    Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration.
    Malone ME, Corrigan OI, Kavanagh PV, Gowing C, Donnelly M, D'Arcy DM.
    Int J Antimicrob Agents; 2013 Oct; 42(4):335-42. PubMed ID: 23920093
    [Abstract] [Full Text] [Related]

  • 20. Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.
    Seibel NL, Shad AT, Bekersky I, Groll AH, Gonzalez C, Wood LV, Jarosinski P, Buell D, Hope WW, Walsh TJ.
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.